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Premedication is important in pediatric anesthesia. This meta-analysis aimed to investigate the role of
dexmedetomidine as a premedicant for pediatric patients.
A systematic literature search was conducted to identify randomized controlled trials comparing
dexmedetomidine premedication with midazolam or ketamine premedication or placebo in children. Two
reviewers independently performed the study selection, quality assessment and data extraction. The original
data were pooled for the meta-analysis with Review Manager 5. The main parameters investigated included
satisfactory separation from parents, satisfactory mask induction, postoperative rescue analgesia, emergence
agitation and postoperative nausea and vomiting.
Thirteen randomized controlled trials involving 1190 patients were included. When compared with
midazolam, premedication with dexmedetomidine resulted in an increase in satisfactory separation from
parents (RD=0.18, 95% CI: 0.06 to 0.30, p=0.003) and a decrease in the use of postoperative rescue analgesia
(RD= -0.19, 95% CI: -0.29 to -0.09, p=0.0003). Children treated with dexmedetomidine had a lower heart rate
before induction. The incidence of satisfactory mask induction, emergence agitation and PONV did not differ
between the groups. Dexmedetomidine was superior in providing satisfactory intravenous cannulation
compared to placebo.
This meta-analysis suggests that dexmedetomidine is superior to midazolam premedication because it
resulted in enhanced preoperative sedation and decreased postoperative pain. Additional studies are needed
to evaluate the dosing schemes and long-term outcomes of dexmedetomidine premedication in pediatric
anesthesia.
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& INTRODUCTION
At least 60% of pediatric patients experience preoperative
anxiety (1). Children may become overly uncooperative at
the time of separation from parents, venipuncture, or
mask application. Untreated anxiety can lead to difficult
induction, increased postoperative pain, greater analgesic
requirements, emergence agitation and even postoperative
psychological effects and behavioral issues (2-7). Despite the
many advances in nonpharmacologic interventions, practi-
tioners still rely on sedative premedicants (8,9).
Midazolam, which causes sedation, anxiolysis and amne-
sia, is one of the most frequently used premedicants (10-14).
It has additional beneficial properties, such as anticonvul-
sant activity, rapid onset and a short duration of action and
it reduces postoperative vomiting (12,15-18). However, it is
far from an ideal premedicant due to its undesirable effects,
which include restlessness, paradoxical reactions, cognitive
impairment, postoperative behavioral changes and respira-
tory depression (19-21). Ketamine is another popular
premedicant that causes dissociative anesthesia and it has
both sedative and analgesic properties (22,23). However, its
side effects, such as excessive salivation, nausea and
vomiting, nystagmus, hallucination and postoperative psy-
chological disturbances have limited its use (24-26).
Dexmedetomidine is a highly selective a-2 adrenoceptor
agonist that provides sedation, anxiolysis and analgesic
effects without causing respiratory depression (27).
Recently, it has been explored extensively in the pediatric
population. Although several randomized controlled trials
have focused on dexmedetomidine premedication in chil-
dren, the sample sizes have been relatively small and
differing conclusions have been reported. Thus, the evi-
dence supporting the use of dexmedetomidine is unclear.
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This meta-analysis was conducted to investigate the effects
of premedication with dexmedetomidine on preoperative
sedation, hemodynamic stability, postoperative pain and
possible adverse events in pediatric patients.
& MATERIALS AND METHODS
Search strategy and trial selection
This systematic review of randomized controlled trials
was performed according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (28). Two researchers (K.P. and SR.W.) indepen-
dently searched the following databases up to April 2014:
MEDLINE, EMBASE and the Cochrane Central Register of
Controlled Trials (CENTRAL). The terms used in the search
strategy were as follows: 1) dexmedetomidine AND (pre-
medication* OR premedicant* OR preoperative OR pre
anesthesia OR pre anaesthesia) AND (child* OR pediatric*
OR paediatric*) for the MEDLINE and CENTRAL searches
and 2) ‘dexmedetomidine’/exp OR dexmedetomidine AND
(premedication* OR premedicant* OR preoperative OR
preanesthesia OR preanaesthesia) AND (child* OR pedia-
tric* OR paediatric*) for the EMBASE search.
All searches were performed without language or pub-
lication date restrictions. The results were collated and
deduplicated in Endnote X7 (Thomson Reuters, New York,
NY). The titles and abstracts were screened before retrieval
of the full articles. Any controversy concerning study
selection or data extraction was resolved by consensus with
a third reviewer (HF.J.). All three authors read the full texts
of all papers and determined which papers should be
included or excluded.
Inclusion and exclusion criteria
To be eligible for this meta-analysis, publications were
required to meet the following four inclusion criteria: 1)
original research comparing premedication with dexmede-
tomidine to premedication with midazolam or ketamine or
placebo as the sole agent administered through noninvasive
routes (oral, rectal, intranasal, sublingual and buccal) in
pediatric patients undergoing elective procedures; 2) a
randomized controlled trial (RCT) study design; 3) dis-
closure of at least one of the following outcome measures:
quality of separation from parents, quality of mask induc-
tion, hemodynamic variables, postoperative pain, recovery
time, time to discharge from the post-anesthesia care unit
(PACU), emergence agitation (EA), postoperative nausea
and vomiting (PONV), shivering and other possible unto-
ward events; and 4) availability of the full-text article.
Data extraction and quality assessment
The following data from the included studies were
extracted and tabulated by two researchers (K.P. and
SR.W.): author, year of publication, sample size, mean age,
intervention measure, type of procedure, anesthesia scheme
and any outcome that met the inclusion criteria.
Corresponding authors were contacted to obtain missing
data if necessary. For the trials assessing different pre-
medication doses, the groups were combined to create a
single pair-wise comparison (29).
The validity was assessed and scored by two researchers
(SR.W. and J.L.) and checked by a third researcher (FH.J.)
using the Jadad scale (30,31), which considers the reporting
and adequacy of randomization (2 points), double blinding
(2 points) and description of drop-outs (1 points).
Statistical analysis
When outcomes of interest were reported by two or more
studies, the included articles were pooled and weighted
using Review Manager (version 5.1, 2011; the Nordic
Cochrane Center, the Cochrane Collaboration). Categorical
outcomes are reported as risk differences (RDs) and 95%
confidence intervals (CIs), while continuous outcomes are
reported as weighted mean differences (WMDs) and 95%
CIs.
Heterogeneity, which was assessed using I2 statistics,
describes the percentage variability in effect estimates (RD
or WMD) that is due to heterogeneity rather than sampling
error. A random-effect model was used for the analysis.
Publication bias was assessed visually with a funnel plot if
more than 10 studies were included.
Sensitivity analyses were performed to further test the
robustness of the results. These analyses included 1) an
assessment of the influence of publication quality (high
versus low quality) on the results and 2) subgroup analysis
according to the different routes of premedication admin-
istration.
& RESULTS
Included trials
A total of 171 of the articles were relevant to the search
terms. Screening of the titles and abstracts revealed that 21
studies were potentially eligible for inclusion. After reading
the full-text articles, 13 trials (published between 2007 and
2014) involving 1190 participants were finally included in
this meta-analysis (32-44) (Table 1). A flow diagram
depicting the trial selection process is shown in Figure 1.
Characteristics of the included trials
Table 1 presents the characteristics of the included trials,
which were all randomized controlled trials that investigated
pediatric patients undergoing different procedures (dental
rehabilitation and tooth extraction, lymph node excision,
herniorrhaphy, circumcision, bone marrow biopsy and aspira-
tion, adenotonsillectomy and others). The children ranged in
age from 2 to 10 years old and most were 4 to 6 years old.
Eleven trials compared dexmedetomidine with midazo-
lam premedication (32-35,37-40,42-44), two compared dex-
medetomidine with ketamine (35,36) and three compared
dexmedetomidine with a placebo (36,38,41). All trials
administered premedication through noninvasive routes,
including oral and transmucosal (intranasal, sublingual and
buccal) administration, at 30-75 min before commencement
of surgery. The dosing scheme for dexmedetomidine was 1-
2 mg/kg for transmucosal premedication or 2.5-4 mg/kg for
oral premedication. Ten trials used balanced inhalational
general anesthesia with sevoflurane or isoflurane and one
trial provided sedation with propofol.
Effect of dexmedetomidine versus midazolam on
separation from parents
Seven trials including 650 patients compared dexmedeto-
midine versus midazolam premedication for satisfactory
separation from parents (32,33,35,37,40,42,43). The meta-
analysis revealed that more children experienced satisfactory
separation following treatment with dexmedetomidine
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Table 1 - Characteristics of the included studies.
Study Intervention time and dosing scheme N Age (y) Procedure Anesthesia Jadad score
Linares Segovia
2014
1. Intranasal dexmedetomidine 1 mg/kg
(0.5 ml) at 60 min before induction
52 4 Inguinal hernia repair, umbilical
hernia repair, circumcision
No details provided 4
2. Oral midazolam 0.5 mg/kg at 60 min
before induction
56 4
Sheta 2013 1. Intranasal dexmedetomidine 1 mg/kg
(1 ml) at 45-60 min before induction
36 3.9 Complete dental rehabilitation Sevoflurane + N2O + local
anesthesia
5
2. Intranasal midazolam 0.2 mg/kg
(1 ml) at 45-60 min before induction
36 4.2
Pant 2013 1. Sublingual dexmedetomidine
1.5 mg/kg (undiluted) at 45 min
before induction
50 4.5 Inguinal hernia repair,
orchidopexy, circumcision
Sevoflurane + N2O + caudal
block
5
2. Sublingual midazolam 0.25 mg/kg
(undiluted) at 20 min before
induction
50 2
Mostafa 2013 1. Intranasal dexmedetomidine 1 mg/kg
at 30 min before induction
32 5 Bone marrow biopsy and
aspiration
Sevoflurane 3
2. Intranasal midazolam 0.2 mg/kg at
30 min before induction
32 4.8
3. Intranasal ketamine 5 mg/kg at
30 min before induction
32 4.9
Gyanesh 2013 1. Intranasal dexmedetomidine 1 mg/kg
(1 ml) at 60 min before IV
cannulation
52 5.1 Magnetic resonance imaging Propofol (sedation only) 5
2. Intranasal ketamine 5 mg/kg (1 ml) at
30 min before IV cannulation
52 4.9
3. Placebo 46 5
Akin 2012 1. Intranasal dexmedetomidine 1 mg/kg
(1.5 ml) at 45-60 min before
induction
45 5 Adenotonsillectomy Sevoflurane + N2O 5
2. Intranasal midazolam 0.2 mg/kg
(1.5 ml) at 45-60 min before
induction
45 6
Ozcengiz 2011 1. Oral dexmedetomidine 2.5 mg/kg at
40-45 min before induction
25 5.5 Esophageal dilatation
procedures
Sevoflurane + N2O 4
2. Oral midazolam 0.5 mg/kg at 40-
45 min before induction
25 4.9
3. Placebo 25 6.2
Mountain 2011 1. Oral dexmedetomidine 4 mg/kg at
30 min before entering the operating
room
22 4 Dental restoration, tooth
extraction
Sevoflurane + N2O + local
anesthesia
4
2. Oral midazolam 0.5 mg/kg at 30 min
before entering the operating room
19 4
Ghali 2011 1. Intranasal dexmedetomidine 1 mg/kg
(0.5 ml) at 60 min before induction
60 8.2 Outpatient adenotonsillectomy Sevoflurane + N2O 4
2. Oral midazolam 0.5 mg/kg at 30 min
before induction
60 8.1
Yuen 2010 1. Intranasal dexmedetomidine 1 mg/kg
(0.4 ml) at 30-75 min before IV
cannulation
79 4 Elective surgery (no details
provided)
No details provided 5
2. Placebo 21 4
Talon 2009 1. Intranasal dexmedetomidine 2 mg/kg
(atomization) at 30-40 min before
induction
50 9.5 Reconstructive surgery Isoflurane + N2O 4
2. Oral midazolam 0.5 mg/kg at
30-40 min before induction
50 10.7
Yuen 2008 1. Intranasal dexmedetomidine 1 mg/kg
(0.4 ml) at 60 min before induction
32 6.1 Orchidopexy, excision of lymph
nodes, circumcision
Isoflurane + N2O + regional
anesthesia
5
2. Intranasal dexmedetomidine 0.5 mg/
kg (0.4 ml) at 60 min before induction
32 6.8
3. Oral midazolam 0.5 mg/kg at 30 min
before induction
32 6.4
Schmidt 2007 1. Transmucosal dexmedetomidine
1 mg/kg at 45 min before surgery
20 8 Excision of lymph nodes,
herniorrhaphy, circumcision
Sevoflurane/isoflurane +
N2O + Regional
anesthesia
3
2. Oral midazolam 0.5 mg/kg at 30 min
before induction
22 9
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(RD = 0.18, 95% CI: 0.06 to 0.30, p= 0.003) (Figure 2).
Subgroup analysis showed that RD = 0.10 (95% CI: -0.12 to
0.31) for intranasal dexmedetomidine versus intranasal
midazolam and RD = 0.24 (95% CI: 0.10 to 0.38) for intranasal
dexmedetomidine versus oral midazolam. However, there
was significant heterogeneity among the pooled studies
(I2 = 73%).
Effect of dexmedetomidine versus midazolam on
mask induction
Six trials including 475 patients compared satisfactory
mask induction in children treated with dexmedetomidine
versus midazolam (32,33,37,39,42,43). The meta-analysis
showed that there was no significant difference between
the groups (RD = -0.01, 95% CI: -0.16 to 0.14, p= 0.88)
(Figure 3). The subgroup analysis revealed that RD = -0.00
(95% CI: -0.44 to 0.43) for intranasal dexmedetomidine versus
intranasal midazolam and RD = 0.01 (95% CI: -0.19 to 0.21) for
intranasal dexmedetomidine versus oral midazolam. This
analysis was influenced by heterogeneity (I2 = 75%).
Effects of dexmedetomidine versus midazolam on
heart rate (HR), systolic blood pressure (SBP) and
oxygen saturation (SpO2) before induction
Two trials including 162 patients compared HR before
induction in children treated with dexmedetomidine versus
midazolam (40,44). The meta-analysis revealed that the HR
before induction was significantly lower in the children
treated with dexmedetomidine (WMD = -15.49 beats/min,
95% CI: -25.13 to -5.86 beats/min, p= 0.002). This analysis
was influenced by heterogeneity (I2 = 74%).
Two trials including 184 patients compared systolic blood
pressure (SBP) before induction in children treated with
dexmedetomidine versus midazolam (35,40). There was
no significant difference between the groups (WMD =
-7.13 mmHg, 95% CI: -19.02 to 4.75 mmHg, p= 0.24). This
analysis was influenced by heterogeneity (I2 = 99%).
Two trials including 184 patients compared SpO2 before
induction in children treated with dexmedetomidine versus
midazolam (35,40). The meta-analysis showed that there
was no significant difference between the groups (WMD =
0.27%, 95% CI: -0.21 to 0.74%, p= 0.27). Additionally, no
significant heterogeneity was observed (I2 = 0%).
Effects of dexmedetomidine versus midazolam on
recovery time and time to discharge from the PACU
Three trials including 204 patients compared the recovery
times of children treated with dexmedetomidine versus
midazolam (33,37,44). There was no significant difference
between the groups (WMD = -0.45 min, 95% CI: -1.26 to
0.35 min, p= 0.27) and no significant heterogeneity was
observed (I2 = 0%).
Three trials including 234 patients compared the time
to discharge from the PACU for children treated with
dexmedetomidine versus midazolam (33,40,44). There was
no significant difference between the groups (WMD =
0.45 min, 95% CI: -2.33 to 3.23 min, p= 0.75). This analysis
was influenced by heterogeneity (I2 = 62%).
Effect of dexmedetomidine versus midazolam on
postoperative rescue analgesia
Five trials including 417 patients compared dexmedeto-
midine with midazolam premedication for postoperative
rescue analgesia (33,37,40,42,44). Meta-analysis revealed
that fewer children needed rescue analgesia when they
were treated with dexmedetomidine (RD = -0.19, 95% CI:
-0.29 to -0.09, p= 0.0003) (Figure 4). The subgroup analysis
showed that RD = -0.20 (95% CI: -0.33 to -0.06) for intranasal
dexmedetomidine versus intranasal midazolam and RD =
-0.11 (95% CI: -0.22 to -0.01) for intranasal dexmedetomidine
versus oral midazolam. This analysis was influenced by
heterogeneity (I2 = 36%); however, no significant heteroge-
neity (I2 = 0%) was detected in the subgroup analysis.
Effects of dexmedetomidine versus midazolam on
EA and PONV
Five trials including 346 patients compared dexmedeto-
midine with midazolam premedication for EA treatment
(33,37-39,42). There was no significant difference between
the groups (RD = -0.03, 95% CI: -0.10 to 0.04, p= 0.36)
(Figure 5). Subgroup analysis showed that RD = -0.05 (95%
CI: -0.16 to 0.06) for intranasal dexmedetomidine versus
intranasal midazolam and RD = -0.03 (95% CI: -0.17 to 0.10)
for oral dexmedetomidine versus oral midazolam. This
analysis was influenced by heterogeneity (I2 = 42%)
Three trials including 226 patients compared dexmedeto-
midine with midazolam premedication for PONV treatment
(33,35,37). The meta-analysis showed that there was no
significant difference between the groups (RD = -0.01, 95%
CI: -0.06 to 0.04, p= 0.83) (Figure 6) and no significant
heterogeneity was detected (I2 = 0%).
Dexmedetomidine versus ketamine
None of the data illustrating the effects of dexmedetomi-
dine versus ketamine could be pooled because similar
outcomes were not reported by any two trials (35,36).
Effect of dexmedetomidine versus placebo on
intravenous cannulation
Two trials including 198 patients compared satisfactory
intravenous cannulation in patients treated with dexmede-
tomidine versus placebo (36,41). The meta-analysis revealed
that more children had satisfactory intravenous cannulation
following treatment with dexmedetomidine (RD = -0.48,
95% CI: -0.92 to -0.04, p= 0.03). However, this analysis was
significantly influenced by heterogeneity (I2 = 91%).
& DISCUSSION
The current meta-analysis revealed that dexmedetomi-
dine premedication of pediatric patients resulted in more
satisfactory separation from parents and a reduced need for
postoperative rescue analgesia compared with midazolam.
The dexmedetomidine-premedicated children had lower
HRs before induction.
Although premedication is often applied, the ideal agent
and the best route of administration remain unclear (45).
Oral premedication is the most widely used route; however,
it results in low bioavailability (46,47). Rectal application is
often painful and medications administered in this way may
be easily expelled from the rectum in young children and
can be problematic for use in older children. Intramuscular
premedication has also been used, but it is invasive and
should be avoided if possible. Transmucosal routes, includ-
ing intranasal, sublingual and buccal administration, have
been shown to be effective because of the rich mucosal
blood supply and because administration via these routes
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Figure 1 - Flow chart of retrieved, excluded and included trials.
Figure 2 - Meta-analysis of satisfactory separation from parents in children treated with dexmedetomidine vs. midazolam.
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allows for the bypass of first-pass metabolism. Moreover,
compliance with nasal sedation is easier to achieve than
compliance with oral sedation in young children (48). In this
meta-analysis, all included trials administered premedica-
tion through noninvasive routes, including oral and
transmucosal (intranasal, sublingual, or buccal) routes.
The pharmacokinetics of midazolam administration has
been well studied. When given orally, its acceptability by
children is only 70% due to poor palatability (49). Intranasal
administration of this medication is effective; however, it
may cause nasal irritation (12). Midazolam results in rapid
sedation and most of the included studies in this meta-
analysis administered intranasal or oral midazolam at
30 min before induction or surgery. Dexmedetomidine, on
the other hand, is colorless, odorless and tasteless and
several studies have investigated its pharmacokinetics in
children (50-54). Oral administration of dexmedetomidine
also results in poor bioavailability. Although intranasal
premedication with midazolam causes nasal irritation, none
of the children treated with dexmedetomidine showed signs
of nasal irritation (33). Intranasal dexmedetomidine is
commonly administered 45-60 min before induction of
surgery because of the relatively slow onset of maximal
sedation.
This meta-analysis revealed that dexmedetomidine was
superior to midazolam in producing satisfactory sedation in
children separated from their parents. The subgroup
analysis showed that premedication with intranasal dexme-
detomidine seemed to be more effective than premedication
with oral midazolam. Oral premedication is associated with
low and variable bioavailability, which may lead to under-
dosage. This fact may explain the reduced effectiveness of
oral midazolam. Notably, larger volumes of intranasally
administered drugs may be swallowed before there is
sufficient time for absorption, leading to reduced bioavail-
ability (33). However, the intranasal drug volumes differed
among the studies (range, 0.3 to 1.5 ml). This finding may
have contributed to the discrepancies among the included
studies and may have introduced bias.
The superiority of dexmedetomidine over midazolam
vanished at the time of mask application. Unlike conven-
tional sedatives, the site of action of dexmedetomidine is the
central nervous system, primarily the locus coeruleus, in
which it induces sedation that parallels natural sleep (55).
Therefore, it is not surprising that external stimulation
facilitates arousal. However, clonidine, which is another a-2
adrenoceptor agonist, was found to be superior to mid-
azolam in providing acceptable levels of sedation during
induction in another meta-analysis (56).
Compared with midazolam premedication, dexmedetomi-
dine premedication reduced the HR during the preoperative
sedation period after induction. The children in both groups
maintained similar normal SpO2 values. Dexmedetomidine
can decrease sympathetic outflow by decreasing plasma
epinephrine and norepinephrine levels, thus leading to
decreases in HR and BP (57,58). Additionally, it has been
shown to have minimal effects on respiration (59,60), which is
its key advantage over other sedative medications.
The most frequently reported adverse events associated
with dexmedetomidine treatment are hypotension and
Figure 3 - Meta-analysis of satisfactory mask induction in children treated with dexmedetomidine vs. midazolam.
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bradycardia (61). Its hemodynamic effects are well known
following intravenous infusion (there is a higher risk of
bradycardia in patients receiving a rapid bolus and a lower
risk in those receiving a continuous infusion). However,
these side effects are seldom observed following non-
intravenous administration. Yuen et al. (43) have shown
that intranasal dexmedetomidine premedication decreases
HR by 11% after administration of 0.5 mg/kg and by 16%
after administration of 1 mg/kg compared with their
respective baseline values within 60 min. Another study
(41) has found that the maximum reduction in SBP is 13.2%
at 60 min and the maximum reduction in HR is 14.9% at
75 min after administration of 1 mg/kg intranasal dexme-
detomidine premedication. None of the included trials
reported significant hypotension or bradycardia requiring
treatment in either group during the study period.
Dexmedetomidine has been demonstrated to effectively
reduce opioid requirements and to potentiate analgesia (61-
63). The current meta-analysis reported the same outcome:
the patients treated with dexmedetomidine required less
postoperative rescue analgesia. Furthermore, the subgroup
analyses demonstrated that the routes of premedication
may not have influenced the superiority of dexmedetomi-
dine over midazolam. Thus, the use of dexmedetomidine
can provide additional analgesic benefits for pediatric
patients following premedication.
Emergence agitation, which is a frequent phenomenon in
children recovering from general anesthesia, creates a
challenging situation (64). Various factors, including pain,
preoperative anxiety, personal temperament, type of surgi-
cal procedure performed and type of anesthetic may
contribute to its occurrence (38). Compared with placebo,
both dexmedetomidine and midazolam have been shown to
reduce EA in children following administration of sevo-
flurane anesthesia (38). This meta-analysis showed that
there was no difference in the incidence of EA between the
dexmedetomidine and midazolam groups. Additionally,
dexmedetomidine had no overall preventive effect on
PONV compared with midazolam. However, no details
pertaining to perioperative antiemetic prophylaxis were
provided for either group; thus, the evidence supporting
this comparison is unclear.
This meta-analysis also compared premedication with
dexmedetomidine to placebo. Only two trials focusing on
satisfactory intravenous cannulation were included and our
analysis was influenced by a high level of heterogeneity.
The results of the comparison of dexmedetomidine versus
ketamine premedication could not be pooled using meta-
analysis due to the limited available data. Ketamine, which
may induce adverse cardiostimulatory effects and post-
operative delirium, is currently used less frequently as a
sole premedicant. Some studies have shown that the
combination of ketamine with other drugs for premedica-
tion results in satisfactory sedation and a reduction in side
effects (65-67). Because this meta-analysis was not designed
to explore the combination of different premedicants, these
studies were not included.
Limitations
This meta-analysis had some limitations. First, the sample
sizes of all the included trials were relatively small and the
methodological quality was variable. Second, differences in
Figure 4 - Meta-analysis of postoperative rescue analgesia in children treated with dexmedetomidine vs. midazolam.
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age may have influenced some of the results because the
pharmacokinetics and pharmacodynamics between
younger and older children vary. Third, the various routes
of premedication may have also introduced bias. Fourth,
significant heterogeneity was observed in some of the
analyses (separation from parents, mask induction, HR
and SBP before induction, time to discharge from the PACU
and satisfactory intravenous cannulation); therefore, the
results should be assessed with caution. Fifth, publication
bias may have affected the precision of some of the
outcomes because positive results are more likely to be
published than negative results; hence, our results may have
been overestimated. Finally, although considerable clinical
data have been reported, dexmedetomidine is not approved
for use in children in any country. Thus, its use in children is
considered ‘off-label’ and exercising caution in its admin-
istration to at-risk patients is warranted.
& CONCLUSIONS
This meta-analysis provides evidence that dexmedetomi-
dine is superior to midazolam premedication in promoting
Figure 5 - Meta-analysis of EA in children treated with dexmedetomidine vs. midazolam. EA: emergence agitation.
Figure 6 -Meta-analysis of PONV in children treated with dexmedetomidine vs. midazolam. PONV: postoperative nausea and vomiting.
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preoperative sedation and decreasing postoperative pain.
Further studies are needed to evaluate the dosing schemes
and long-term outcomes of preoperative dexmedetomidine
administration in pediatric anesthesia.
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